NovoCure
NVCR
282 hedge funds and large institutions have $8.15B invested in NovoCure in 2020 Q3 according to their latest regulatory filings, with 66 funds opening new positions, 78 increasing their positions, 98 reducing their positions, and 47 closing their positions.
125% more funds holding in top 10
Funds holding in top 10: 4 → 9 (+5)
99% more capital invested
Capital invested by funds: $4.1B → $8.15B (+$4.05B)
40% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 47
14% more call options, than puts
Call options by funds: $193M | Put options by funds: $169M
7% more funds holding
Funds holding: 264 → 282 (+18)
3.61% more ownership
Funds ownership: 68.86% → 72.47% (+3.6%)
20% less repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 98
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$377M |
| 2 |
BlackRock
New York
|
+$134M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$106M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$58.6M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$81.8M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$80.5M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$44.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$38.6M |
| 5 |
DCP
Darsana Capital Partners
New York
|
-$30M |
NVCR Hedge Fund Activity: Q3 2020 in Review
282 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q3 2020, worth a combined $8.15B — up 99% from $4.1B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new NVCR positions and 47 closed out — a net gain of 19 holders — while 78 added to existing stakes and 98 trimmed.
The largest buyer was Capital International Investors, adding an estimated $377M. The largest seller was Renaissance Technologies, cutting an estimated $81.8M.
- 282 institutional investors held NovoCure (NVCR) as of Q3 2020, up from 264 in Q2 2020.
- Funds reported $8.15B of NovoCure stock for Q3 2020, up 99% quarter-over-quarter.
- 66 funds opened new NovoCure positions in Q3 2020 and 47 closed out, a net change of +19 holders.
- The largest NovoCure buyer in Q3 2020 was Capital International Investors, an estimated $377M added.
- The largest NovoCure seller in Q3 2020 was Renaissance Technologies, an estimated $81.8M sold.
Based on aggregated 13F filings for Q3 2020.